557 The MI-selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of patients with mild to moderate Alzheimer's disease

Autor:	W. Offen, N. Bodick
Rok vydání:	1996
Předmět:	Aging business.industry General Neuroscience Cognition Disease Pharmacology Muscarinic agonist chemistry.chemical_compound chemistry Medicine Neurology (clinical) Geriatrics and Gerontology business Xanomeline Developmental Biology
Zdroj:	Neurobiology of Aging. 17:S138-S139
ISSN:	0197-4580
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::e60c66937119b27897ac8a726b90353b https://doi.org/10.1016/s0197-4580(96)80559-8 Zobrazit plný text záznamu Full Text from ScienceDirect